Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy
Protagenic Therapeutics (NASDAQ: PTIX) just pulled off a biotech plot twist worthy of a season finale.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | AQR Capital Management Cliff Asness | 0 | $0 | 0% | |
2. | Touradji Capital Management Paul Touradji | 0 | $0 | 0% | |
3. | Renaissance Technologies Jim Simons | 0 | $0 | 0% |
Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$2.61 | 6,000 | $15,660.00 | 25,000 | 2010-06-01 | Filing |
Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$2.60 | 215,100 | $559,668.69 | 947,415 | 2013-11-19 | Filing | |
$3.20 | 31,600 | $101,085.24 | 1,162,515 | 2013-11-08 | Filing | |
$2.78 | 100,000 | $278,120.00 | 1,194,115 | 2013-10-01 | Filing | |
$1.25 | 100,000 | $125,000.00 | 1,294,115 | 2013-06-28 | Filing | |
$2.00 | 100,000 | $200,000.00 | 1,394,115 | 2012-02-22 | Filing |